Breakthrough in Vascular Research: The Microfluidic Vessel-on-Chip Platform

At the helm of a new era in vascular research, Prof. Matthias Meier's team at the Helmholtz Pioneer Campus introduces a cutting-edge microfluidic vessel-on-chip technology.

This innovation leverages human stem cells to study of vascular diseases, signaling a leap towards personalized treatments and reduced animal testing.


The fight against cardiovascular diseases, leading causes of death worldwide, is hampered by the inadequacies of traditional models to mimic human vascular conditions accurately. The search for more reliable human blood vessel models is urgent, as existing methods fall short of capturing the complexity of human diseases.


Addressing this critical need, the team developed a sophisticated microfluidic vessel-on-chip platform. Utilizing human pluripotent stem cell-derived endothelial cells, this platform replicates the dynamic environment of human blood vessels in a genomic defined setup. The microfluidic design allows precise control over the biochemical and mechanical stimuli affecting the cells, paving the way for groundbreaking insights into vascular health and disease.


Through meticulous experimentation, the team demonstrated the platform's ability to model the early stages of atherosclerosis. The stem cell-derived endothelial cells were subjected to a flow of oxidized LDL and free fatty acids within the microfluidic channels, simulating conditions seen in patients with metabolic syndrome. This exposure led to observable changes in cell behavior and protein expression, closely resembling those found in human disease states.


The development of this microfluidic vessel-on-chip technology by Prof. Meier's team marks a pivotal advancement in vascular research. It opens new avenues for exploring disease mechanisms, testing therapeutic interventions, and advancing towards personalized medicine. Beyond its scientific merits, this technology embodies a commitment to ethical research by offering an alternative to animal models, aligning with global efforts to conduct humane and relevant scientific inquiry. Through this breakthrough, the team at the Helmholtz Pioneer Campus not only advances our understanding of vascular diseases but also sets a new standard for research in the life sciences.

Link to publication